文献速递泌尿男性生殖肿瘤

LIM和SH3蛋白1在肾透明细胞癌中的表达及其对786-O细胞侵袭和迁移的影响

[Expression of LIM and SH3 protein 1 in renal clear cell carcinoma and its effects on invasion and migration of renal clear cell carcinoma 786-O cells].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

该研究采用免疫组化检测41例肾透明细胞癌及癌旁组织中LASP1蛋白表达,并用Western blot检测10例伴或不伴淋巴结转移的肾癌组织,再以siRNA沉默786-O细胞LASP1后评估增殖、侵袭、迁移及EMT相关蛋白。结果显示癌组织LASP1阳性率90.2%(37/41)高于癌旁组织29.3%(12/41,P=0.002),且与淋巴结转移和TNM分期正相关;沉默LASP1后786-O细胞增殖、侵袭、迁移能力降低,E-cadherin升高、N-cadherin和Vimentin降低。

要点

  • 肾透明细胞癌组织LASP1阳性率90.2%(37/41),高于癌旁组织29.3%(12/41,P=0.002)。
  • LASP1表达与肾癌淋巴结转移和TNM分期呈正相关(均P<0.05)。
  • 沉默LASP1可降低786-O细胞增殖、侵袭和迁移能力,并伴随EMT标志物变化。

核心结论

  • LASP1蛋白在肾透明细胞癌中高表达,其高表达可能与肾癌的发生发展有关,并可能通过EMT调节肾癌细胞的侵袭和迁移能力,促进肿瘤的淋巴结转移。

研究设计与样本

  • 免疫组化检测41例肾透明细胞癌患者肿瘤组织及其配对癌旁组织中LASP1蛋白表达,并分析其与临床病理特征的关系。
  • Western blot法检测10例伴或不伴淋巴结转移的肾透明细胞癌组织中LASP1蛋白表达差异。
  • 以小干扰RNA(siRNA)技术转染786-O细胞,采用Western blot法检测LASP1 siRNA对LASP1蛋白的干扰效果及EMT通路相关蛋白表达影响。
  • 采用细胞计数盒8(CCK-8)法和Transwell实验检测下调LASP1蛋白表达对786-O细胞增殖、侵袭和迁移能力的影响。

主要发现

  • LASP1蛋白在肾透明细胞癌组织中的阳性表达率为90.2%(37/41),明显高于其在癌旁组织中的阳性表达率29.3%(12/41,P=0.002)。
  • LASP1在肾癌组织中的表达与肾癌的淋巴结转移和TNM分期呈正相关(均P<0.05)。
  • Western blot法检测显示,LASP1蛋白在癌旁正常组织、无淋巴结转移肾癌组织和有淋巴结转移肾癌组织中的相对表达量分别为0.696±0.053、1.459±0.628和2.692±0.186,差异有统计学意义(P=0.001)。
  • 沉默786-O细胞中LASP1蛋白的表达后,786-O细胞的增殖、侵袭和迁移能力均明显降低。
  • LASP1 siRNA转染786-O细胞48 h后,siRNA转染组、阴性对照组和空白对照组E-cadherin蛋白相对表达量分别为0.848±0.020、0.671±0.018和0.691±0.037,siRNA转染组E-cadherin表达明显增高(P<0.05);N-cadherin相对表达量分别为0.449±0.047、0.613±0.018和0.633±0.045,siRNA转染组N-cadherin表达明显降低(P<0.05);Vimentin相对表达量分别为0.477±0.029、0.598±0.069和0.633±0.045,siRNA转染组Vimentin表达明显降低(P<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the expression of LIM and SH3 protein 1 (LASP1) in renal cell carcinoma and its significance in the invasion and migration of renal clear cell carcinoma 786-O cell line. Methods: The expression level of LASP1 in 41 cases of renal cell carcinoma tissues and normal renal tissues was analyzed by immunohistochemistry. The relationship between the expression level of LASP1 and clinical characteristics was further analyzed. Expression of LASP1 in 10 cases of tumor tissues with or without lymph node metastasis was analyzed by Western blot. Furthermore, small interfering RNA (siRNA) targeting LASP1 was constructed and transfected into 786-O cells to downregulate LASP1 expression. The interference effect of LASP1 siRNA on LASP1 protein and the expression of related proteins in epithelial mesenchymal transition (EMT) pathway were detected by Western blot. The effects of LASP1 knockdown on cell proliferation, migration and invasion and gene expression were then assessed using CCK8 assay, transwell cell migration system and western blot analysis, respectively. Results: The positive rate of LASP1 expression in renal clear cell carcinoma tissues was 90.2% (37/41), which was significantly higher than that in the adjacent tissues (29.3%, P=0.002). The expression of LASP1 in renal cell carcinoma was positively correlated with lymph node metastasis and TNM stage of renal cell carcinoma (P<0.05). The results of Western blot showed that LASP1 (0.696±0.053) was highly expressed in renal cell carcinoma (1.459±0.628), especially in cases with lymph node metastasis (2.692±0.186, P<0.05). The LASP1 siRNA remarkably down-regulated the expression of LASP1 protein in 786-O cells. The abilities of proliferation, invasion and migration of 786-O cells were decreased significantly in the LASP1 siRNA groups.The relative expression of E-cadherin protein in the siRNA group (0.848±0.020) was significantly higher than those in the siRNA-NC group (0.671±0.018) and control group (0.691±0.037, P<0.05). The relative expression of N-cadherin protein in the siRNA group (0.449±0.047) was significantly lower than those in the siRNA-NC group (0.613±0.018) and control group (0.633±0.045, P<0.05). The relative expression of vimentin protein in the siRNA group (0.477±0.029) was significantly lower than those in the siRNA-NC group (0.598±0.069) and control group (0.633±0.045, P<0.05 for both). Conclusions: LASP1 is highly expressed in renal clear cell carcinoma, which is closely related to the development of the cancer. The effects of LASP1 on the invasion and migration of 786-O cells and lymph node metastasis may be related to the EMT. 目的: 分析LIM和SH3蛋白1(LASP1)在肾癌组织中的表达及其与肾癌患者临床病理特征的关系,探讨沉默LASP1表达对肾透明细胞癌786-O细胞侵袭和迁移能力的影响。 方法: 应用免疫组织化学染色检测41例肾透明细胞癌患者肿瘤组织及其配对的癌旁组织中LASP1蛋白的表达水平,并分析LASP1蛋白表达与患者临床病理特征的关系。采用Western blot法检测10例伴或不伴淋巴结转移肾透明细胞癌组织中LASP1蛋白的表达差异。以小干扰RNA(siRNA)技术转染786-O细胞,采用Western blot法检测LASP1 siRNA对LASP1蛋白的干扰效果以及对上皮间质转化(EMT)通路中相关蛋白的表达影响。采用细胞计数盒8(CCK-8)法和Transwell实验检测下调LASP1蛋白表达对786-O细胞增殖、侵袭和迁移能力的影响。 结果: LASP1蛋白在肾透明细胞癌组织中的阳性表达率为90.2%(37/41),明显高于其在癌旁组织中的阳性表达率(29.3%,12/41; P=0.002)。LASP1在肾癌组织中的表达与肾癌的淋巴结转移和TNM分期呈正相关(均P<0.05)。Western blot法检测结果显示,LASP1蛋白在癌旁正常组织、无淋巴结转移肾癌组织和有淋巴结转移肾癌组织中的相对表达量分别为0.696±0.053、1.459±0.628和2.692±0.186,差异有统计学意义(P=0.001)。沉默786-O细胞中LASP1蛋白的表达后,786-O细胞的增殖、侵袭和迁移能力均明显降低。LASP1 siRNA转染786-O细胞48 h后,siRNA转染组、阴性对照组和空白对照组786-O细胞中上皮表型标志物E-cadherin蛋白的相对表达量分别为0.848±0.020、0.671±0.018和0.691±0.037,siRNA转染组E-cadherin蛋白的表达明显增高(P<0.05);siRNA转染组、阴性对照组和空白对照组786-O细胞中间质表型标志物N-cadherin蛋白的相对表达量分别为0.449±0.047、0.613±0.018和0.633±0.045,siRNA转染组N-cadherin蛋白的表达明显降低(P<0.05);siRNA转染组、阴性对照组和空白对照组786-O细胞中间质表型标志物Vimentin蛋白的相对表达量分别为0.477±0.029、0.598±0.069和0.633±0.045,siRNA转染组Vimentin蛋白的表达明显降低(P<0.05)。 结论: LASP1蛋白在肾透明细胞癌中高表达,其高表达可能与肾癌的发生发展有关,并可能通过EMT调节肾癌细胞的侵袭和迁移能力,促进肿瘤的淋巴结转移。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Jin B, Gao L, Li W, et al. [Expression of LIM and SH3 protein 1 in renal clear cell carcinoma and its effects on invasion and migration of renal clear cell carcinoma 786-O cells]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28316213. doi:10.3760/cma.j.issn.0253-3766.2017.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。